A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism
Status:
Terminated
Trial end date:
2021-05-25
Target enrollment:
Participant gender:
Summary
This is a multi-center, placebo-controlled, randomized, double-blind, multiple-ascending dose
study in patients with hypoparathyroidism.
The total duration of study medication treatment will be 13 weeks and includes a Fixed-Dose
Treatment period and a Dose Titration Treatment period. The Fixed-Dose Treatment period
consists of multiple daily dosing at a fixed dose level. Once patients have completed the
Fixed-Dose Treatment period, patients will enter the Dose Titration Treatment period where
PCO371 (or placebo), oral calcium and oral active vitamin D can each be titrated according to
the patient's albumin-corrected serum calcium level.